Comparison 2.

Mepolizumab (IV) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Rate of clinically significant exacerbations	3	751	Rate Ratio (Random, 95% CI)	0.53 [0.44, 0.64]
1.1 Eosinophilic	3	751	Rate Ratio (Random, 95% CI)	0.53 [0.44, 0.64]
2 Rate of exacerbations requiring emergency department treatment or admission	2	690	Rate Ratio (Random, 95% CI)	0.52 [0.31, 0.87]
2.1 Eosinophilic	2	690	Rate Ratio (Random, 95% CI)	0.52 [0.31, 0.87]
3 Rate of exacerbations requiring admission	2	690	Rate Ratio (Random, 95% CI)	0.61 [0.33, 1.13]
3.1 Eosinophilic	2	690	Rate Ratio (Random, 95% CI)	0.61 [0.33, 1.13]
4 People with one or more exacerbations	1	61	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.61, 1.09]
4.1 Eosinophilic	1	61	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.61, 1.09]
5 Health‐related quality of life (AQLQ)	2	369	Mean Difference (Random, 95% CI)	0.21 [‐0.06, 0.47]
5.1 Eosinophilic	2	369	Mean Difference (Random, 95% CI)	0.21 [‐0.06, 0.47]
6 Health‐related quality of life (ACQ)	2	369	Mean Difference (Fixed, 95% CI)	‐0.11 [‐0.32, 0.09]
6.1 Eosinophilic	2	369	Mean Difference (Fixed, 95% CI)	‐0.11 [‐0.32, 0.09]
7 Health‐related quality of life (SGRQ)	1	382	Mean Difference (Random, 95% CI)	‐6.4 [‐9.65, ‐3.15]
7.1 Eosinophilic	1	382	Mean Difference (Random, 95% CI)	‐6.4 [‐9.65, ‐3.15]
8 Pre‐bronchodilator FEV1 (litres)	2	690	Mean Difference (Random, 95% CI)	0.08 [0.02, 0.15]
8.1 Eosinophilic	2	690	Mean Difference (Random, 95% CI)	0.08 [0.02, 0.15]
9 Serious adverse events	3	751	Risk Ratio (M‐H, Random, 95% CI)	0.59 [0.37, 0.94]
9.1 Eosinophilic	3	751	Risk Ratio (M‐H, Random, 95% CI)	0.59 [0.37, 0.94]
10 Adverse events leading to discontinuation	3	751	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.18, 2.92]
10.1 Eosinophilic	3	751	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.18, 2.92]
11 Serum eosinophil level (cells/microlitre)	1		Mean Difference (Fixed, 95% CI)	‐170.0 [‐228.00, ‐110.00]
11.1 Eosinophilic	1		Mean Difference (Fixed, 95% CI)	‐170.0 [‐228.00, ‐110.00]